Table 3. Clinical and laboratory parameters adversely impacting overall survival in 889 patients with primary myelodysplastic syndromes stratified by the absolute monocyte count (AMC<0.3 × 109/l vs AMC ⩾0.3 × 109/l) and lymphocyte-to-monocyte ratio (LMR; LMR<5 vs LMR⩾5).
| Variables | Univariate analysis, HR (95% CI) P-value | Multivariate analysis P-value, AMC<0.3 × 109/l vs AMC⩾0.3 × 109/l | Multivariate analysis P-value, LMR<5 vs LMR⩾5 | Multivariate analysis, HR (95% CI) P-value of higher LMR |
|---|---|---|---|---|
| Older age (years) | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| Gender (male) | <0.0001 | 0.003 | 0.004 | 0.003 |
| Lower hemoglobin g/dl | <0.0001 | |||
| Hemoglobin <10 g/dl | <0.0001 | <0.0001 | 0.01 | <0.0001 |
| Lower leukocyte count × 109/l | 0.05 | |||
| Lower platelet count × 109/l | <0.0001 | |||
| Low platelet count <100 × 109/l | <0.0001 | 0.003 | 0.001 | 0.002 |
| Absolute neutrophil count <0.8 × 109/l | 0.0002 | 0.5 | 0.3 | 0.5 |
| Increased circulating blasts % | <0.0001 | 0.001 | 0.001 | 0.002 |
| Increased bone marrow blast % | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| IPSS-R, cytogenetic risk group | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| IPSS-R, risk category | <0.0001 | |||
| Lower absolute monocyte count | 0.002 | |||
| Absolute monocyte count <0.3 × 109/l vs ⩾0.3 × 109/l | 1.3 (1.1–1.5) 0.0003 | 0.09 | ||
| Higher LMR | <0.0001 | 0.02 | ||
| LMR<5 vs LMR⩾5 | 1.1 (1.0–1.3) 0.03 | 0.4 |
Abbreviations: AMC, absolute monocyte count; CI, confidence interval; HR, hazard ratio; IPSS-R, Revised International Prognostic Scoring System. Reference normal range: AMC (0.3–0.9) × 109/l, (Mayo Clinic Laboratory). The bold values here represent the P-values that were found to be significant on analysis.